Artiva Biotherapeutics Reports $25M Net Loss and $368.6M in Assets for Q2 2026

Artiva Biotherapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $25.0 million for the quarter, compared to a loss of $21.3 million in the same period last year, marking an increase of approximately 17%. For the six months ended June 30, 2026, the net loss was $48.5 million, up from $41.6 million in the prior year. Operating expenses for the quarter totaled $26.9 million, a rise from $22.8 million in the previous year, driven primarily by increased research and development costs associated with the ongoing clinical trials of its lead product candidate, AlloNK.

Artiva's total assets as of June 30, 2026, reached $368.6 million, a substantial increase from $130.9 million at the end of 2025. This growth was largely attributed to a successful public offering in May 2026, where the company raised $300 million in gross proceeds by issuing 23.9 million shares of common stock and pre-funded warrants. The net proceeds from this offering amounted to $282.7 million after deducting related costs. The company’s cash, cash equivalents, and investments stood at $349.4 million, providing a solid liquidity position to support its ongoing operations and clinical development activities.

In terms of operational metrics, Artiva has made notable progress in its clinical trials. As of April 30, 2026, over 70 patients with autoimmune diseases had been treated with AlloNK across various clinical trials, with more than 40 clinical sites activated globally. The company is currently prioritizing refractory rheumatoid arthritis (RA) as the lead indication for AlloNK, which has received Fast Track Designation from the FDA. The company plans to initiate a Phase 3 randomized controlled trial for AlloNK in refractory RA in the second half of 2026, with expectations to report primary efficacy data in the second half of 2028.

Artiva's research and development expenses for the quarter increased to $21.9 million, up from $17.9 million in the same quarter of the previous year. This increase was primarily due to heightened external costs related to the AlloNK program. The company anticipates that its research and development expenses will continue to rise as it advances its clinical programs and prepares for potential commercialization. Despite the ongoing losses, Artiva remains focused on its strategic objectives, including the development of its NK cell-based therapies and expanding its market presence in the autoimmune disease sector.

Looking ahead, Artiva Biotherapeutics acknowledges the need for additional funding to support its operations and development activities. The company plans to finance its future capital requirements through public or private equity or debt financings, as well as potential collaborations. However, it cautions that there are no guarantees regarding the ability to secure such funding on favorable terms, which could impact its research and development programs and overall business strategy.